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Abstract
Background: Histone H3K4 trimethylation (H3K4 me3) is found in active euchromatic regions and plays an
important role in podocyte function in which actin filaments are abundant in the foot processes. The pathogenesis
of membranous nephropathy (MN), the most prevalent cause of primary nephrotic syndrome in the middle-aged
and elderly, is podocyte dysfunction.
Methods: We investigated the role of H3K4 me3 in podocyte dysfunction in nephrotic syndrome using cultured
podocytes and a mouse proteinuria model induced by LPS. We examined renal biopsy specimens from six patients
with nephrotic syndrome caused by Phospholipase-A2-Receptor-positive primary MN.
Results: H3K4 me3 exhibited a pattern of nuclear expression in podocytes of the kidneys from patients with MN.
The overlapping expression of H3K4 me3 and cathepsin L (a potent endoprotease causing the breakdown of actin-
associated protein within lysosomal compartments in kidney podocytes) were higher in patients with MN compared with
the controls. Histone H3K4 me3 in kidney podocytes was negatively correlated with synaptopodin, an actin-associated
protein in podocytes, and the expression was positively correlated with the proteinuria levels in patients with MN. Histone
H3K4 me3 levels were elevated in podocytes of LPS-treated mice, combined with an increase in podocyte swelling, an
elevation of serum creatinine and urine albumin, increased cathepsin L, and decreased synaptopodin expression. Histone
H3K4 me3 levels at the cathepsin L promoter were elevated in LPS-exposed mouse kidneys. The administration of shRNA
against MLL3 (an H3K4 methyltransferase) to LPS-treated mice and cultured podocytes co-cultured with LPS-stimulated
macrophages ameliorated podocyte swelling, an elevation in the serum creatinine and urine albumin levels and an
increased expression of histone H3K4 me3 and cathepsin L, and a decreased expression of synaptopodin and increase in
histone H3K4 me3 levels at the cathepsin L promoter.
Conclusions: Histone H3K4 me3 upregulation may be involved in podocyte dysfunction and the pathophysiology of MN.
Targeting this epigenetic signature of histone H3K4 me3 followed by modulating the actin dynamics may be an effective
strategy to ameliorate the consequences of MN.
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Background
The median age of onset of membranous nephropathy
(MN) is in the early 50s, and is the most important cause
of the nephrotic syndrome in the elderly (aged > 65 years).
MN pathogenesis involves podocyte injury caused by vi-
ruses, drugs, or autoimmunity deficiency. Podocytes are
the largest cells in the glomerulus and play a central role
in the glomerular filtration barrier of the kidney [1, 2].
Podocytes contain a well-developed Golgi complex, with
lysosomes containing proteasomal enzymes (e.g., cathep-
sin L) [3]. Large numbers of microtubules, microfilaments,
and intermediate filaments are present in the cytoplasm,
and actin filaments are particularly abundant in the foot
processes where they connect the slit membrane with the
glomerular basement membrane. Several studies have
described molecular changes in the podocytes of patients
with MN [2, 4, 5].
Histone modifications are key changes in the chromatin
architecture that correlate with the changes in gene ex-
pression. The closed chromatin template is inaccessible to
regulatory cofactors and thus is transcriptionally
suppressed. In contrast, the open conformation enables
the entry and recruitment of key transcriptional enzymes,
such as RNA pol II. Trimethylation of histone H3 on
lysine 4 (H3K4 me3) is found in active euchromatin but
not in silent heterochromatin [6, 7].
To investigate the role of H3K4 me3 in the patho-
physiology of nephrotic syndrome, we examined renal
biopsy specimens from six patients with nephrotic syn-
drome that was caused by primary MN. We studied
H3K4 me3 in a mouse proteinuria model induced by
LPS and in cultured podocytes.
Methods
Subjects and samples
Archival renal biopsy tissue, serum, and urine samples were
available from six patients with primary MN. The tissues
were classified by stage according to the Ehrenreich-Churg
classification system using transmission electron micros-
copy, and the immunohistochemical differences between
the three stages were determined. Cryosections of kidney bi-
opsy specimens were obtained from patients with MN and
stained with anti-human IgG, IgA, IgM, C3, C4, and C1q
antibodies (Dako, USA). Sections (4 μm) embedded in par-
affin were stained with hematoxylin and eosin, periodic
acid-Schiff stain, periodic acid-methenamine-silver stain,
Masson trichrome stain, and immunohistochemically ana-
lyzed as described below. All subjects provided informed
written consent. This study was approved by the Asahikawa
Medical University Institute Ethics Committee. Patients with
minimal change (N= 2), focal segmental glomerular scler-
osis (FSGS, N= 2), and AL amyloidosis (N= 3) were exam-
ined as the human controls of patients with other
causes of nephrotic syndrome. Three controls were
subjected to a renal biopsy with finding of microhe-
maturia without proteinuria and no pathological find-
ings of glomerulonephropathy (control A (ConA)).
Another age-matched control was used as a frozen
and paraffin tissue section of a healthy human adult
normal kidney (control B (ConB), BioChain Institute,
Inc., CA, USA).
Histological analysis
The kidneys were fixed in a solution of buffered paraformal-
dehyde, embedded in paraffin, and sectioned (4 μm) in an
LPS-induced proteinuria model. For immunohistochemistry,
paraffin-embedded kidney sections from human subjects
and mice were incubated with antibodies against nephrin
(NOVUS BIOLOGICALS, Littleton, CO, USA), histone
H3K4 me3 (EPIGENETEK, Farmingdale, NY, USA), cathep-
sin L (R&D Systems, Inc., Minneapolis, MN, USA), Wilm’s
tumor-1 protein (WT-1, DAKO, USA), synaptopodin
(PROGEN Biotechnik, Heidelberg, German), and anti-GFP
(anti-GFP-tag, rabbit polyclonal antibody; AnaSpec, Inc.,
Fremont, CA, USA), NEPH-1 (KIRREL1, BIOSS
ANTIBODIES, Woburn, MA, USA), phospholipase A2 re-
ceptor 1 (Anti-PLA2R1, ATLAS ANTIBODIES, Stockholm,
Sweden), followed by an incubation with a biotinylated
secondary antibody and streptavidin-HRP. Tissue sections
were visualized using TACS Blue Label (Trevigen Inc.,
Gaithersburg, MD, USA) to generate a dark blue color.
For immunofluorescence, Alexa Fluor 594 goat anti-
mouse IgG (H + L) (ab150116; Abcam, Cambridge, UK),
Alexa Fluor 488 donkey anti-rabbit IgG (H + L) (A21206;
Life Technologies, Carlsbad, CA, USA), Alexa Fluor 594
goat anti-rat IgG (H + L) (ab150160; Abcam), Alexa Fluor
594 donkey anti-goat IgG (H + L) (ab150132; Abcam),
Alexa Fluor 594 donkey anti-rabbit IgG (H + L)
(ab150076, Abcam), Alexa Fluor 488 goat anti-mouse IgG
(H + L) (ab150113, Abcam) for the secondary antibody
and a fluorescence microscope for visualization (BZ-X700,
KEYENCE, Osaka, Japan) were used.
Glomerular images (4–10) from mouse and human
kidneys were captured with a 40× objective for each
case. All of the regions of interest (ROIs) in each glom-
eruli were measured automatically, after which the
results were normalized for each glomerular area, and
the percent area was determined using the image
analyzer (KEYENCE, Osaka, Japan). All final measure-
ments used the mean values of 4–10 glomerular images
captured from each case. The mean ± standard error of
three measurements of the merged yellowish areas of
H3K4 me3 and cathepsin L staining in the same glom-
eruli of the control was 0.70% ± 0.16%.
Transmission electron microscopy
Renal tissue was incubated with 4% paraformaldehyde for
2 h and embedded in LR white resin (London Resin
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Company Limited, London, UK). Ultrathin sections were
prepared using a diamond knife (DIATOME, Switzerland)
and microtome (Sakura Co. Ltd, Tokyo, Japan). The sec-
tions were mounted on a grid mesh coated with polyvinyl
formal (Okenshoji Co Ltd, Tokyo, Japan) and dual-stained
with uranyl acetate in 10% ethanol (w/v) and lead citrate
in 0.1% (w/v) 0.1 M NaOH. Analyses were performed
using a transmission electron microscope (Hitachi, Tokyo,
Japan). The podocyte cell area was measured using the
image analyzer (Hitachi, Tokyo, Japan).
Western blotting
Kidney tissues from mice with an LPS-induced model of
proteinuria were weighed, divided into pieces that in-
cluded the cortex using a clean razor blade, and stored
in Allprotect Tissue Reagent (QIAGEN, Venlo, Limburg,
Netherlands). The tissue was then disrupted and homog-
enized using a Dounce homogenizer (TissueLyser,
QIAGEN) and transferred to microcentrifuge tubes.
RNA, DNA, and protein were extracted using the All-
PrepDNA/RNA/Protein Mini kit (QIAGEN). Equal
amounts of protein as determined using the bicinchoni-
nic acid method (Thermo Fisher Scientific K.K, MA,
USA) were diluted in SDS sample buffer [62.5 mM Tris/
HCl (pH 6.8), 1.25% (w/v) SDS, 25% (w/v) glycerol] and
boiled for 2–3 min. Samples (10 μg/10 μL) were then
loaded onto polyacrylamide gels (ePAGEL; ATTO,
Tokyo, Japan). ECL DualVue markers (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) were used as mo-
lecular weight standards. After electrophoresis (AE-6351
PageRun, ATTO), the gels were transferred to a
Hybond-P PVDF (Immobilon-P, 0.04 mm; EMD
Millipore Corporation, Billerica, MA, USA) using wet
transfer equipment (Mini-PROTEAN Tetra; Bio-Rad,
Tokyo, Japan). Nonspecific binding was blocked by incu-
bating the membrane in Amersham ECL Prime Blocking
Agent (RPN418) or 5% nonfat dried milk and 0.1% (v/v)
Tween 20 in TBS (TBS-T) for 1 h at room temperature
in a covered container. The membrane was rinsed by
changing the wash buffer twice. The blocked membrane
was incubated overnight at 4 °C in blocking buffer con-
taining the following primary antibodies: histone H3K4
me3 (Epigentek, Farmingdale, NY, USA), cathepsin L (R &
D Systems, Inc., Minneapolis, MN, USA), and synaptopo-
din (p-19; Santa Cruz Biotechnologies, Santa Cruz, CA,
USA). The membrane was washed for 15 min three times
in TBS-T, followed by incubation for 60 min at room
temperature with a horseradish peroxidase (HRP)-conju-
gated secondary antibody (GE Healthcare Bio-Sciences
AB) diluted 1:10,000 in wash buffer. The membrane was
washed for 15 min three times with TBS-T and visualized
using the ECL Prime Western Blotting Detection System
(GE Healthcare Bio-Sciences AB). Images were captured
using a CCD camera (LAS-3000, GE Healthcare).
Determination of H3K4 me3 levels from acid extraction
material
H3K4 me3 levels were determined using a material iso-
lated by acid extraction (The EpiQuik™ Total Histone
Extraction Kit, EPIGENETEK, Farmingdale, NY, USA),
and global tri-methylation of histone H3-K4 was mea-
sured using the EpiQuik Global Tri-Methyl Histone H3-
K4 Quantification Kit determined by a sandwich enzyme-
linked immunosorbent assay (ELISA). The EpiQuik Total
Histone H3 Quantification Kit (EPIGENETEK, sandwich
ELISA) was used for measuring the modified histone H3
content of the samples for standardization.
LPS-induced model of proteinuria
Male C57BL/6 mice weighing 15–20 g were housed in
standard cages in climate- and light-controlled rooms
(12 h light–dark cycle) at 22 °C with free access to food
and water. All animal studies were approved by the Asa-
hikawa Medical University Animal Institute Committee.
We induced proteinuria in male mice via an LPS injec-
tion as previously described [8]. Mice were injected with
ultrapure LPS (100 μg intraperitoneally [i.p.]) (LPS-EK
ULT Escherichia coli K12, Invivogen, San Diego, CA,
USA). After 24 h, the LPS administration (50 μg) was re-
peated, and shRNA was injected as described below. The
mice were sacrificed 24 h after shRNA injection. Urine
and plasma samples were assessed for albumin (Quanti-
Chrom BCG Albumin Assay Kit, BioAssay Systems,
Hayward, CA, USA) and creatinine levels (QuantiChrom
Creatinine Assay Kit, BioAssay Systems, Hayward, CA,
USA) according to the manufacturer’s protocols.
Albuminuria in mice was determined as arbitrary units
of albumin per milligram of creatinine.
In vivo gene delivery of shRNA targeting MLL3
In vivo hydrodynamic gene delivery was achieved as previ-
ously described (1), with some modifications in an LPS-
induced model of proteinuria. We then inoculated the mice
(N= 10 per group) with 100 μg LPS i.p., and 24 h after ad-
ministration, we administrated another 50 μg LPS i.p. and
injected anti-nephrin antibody-flag-shRNA through the
penile vein. The MaxCarrierT3 Conjugation Kit (Bioo
Scientific Corporation, Austin, TX, USA) was used to con-
jugate the T3 carrier to an antibody against nephrin spe-
cific to an extracellular protein domain on podocytes
(R&D Systems, Inc., Minneapolis, MN, USA). A mixture
of 20 μg shRNA against MLL3, a control, and a plasmid-
encoding GFP was added to the T3 conjugate along with
in vivo-jet PEI cationic polymer transfection reagent
(1 μL) (Polyplus-transfection Inc., New York, NY, USA) in
a 5% glucose solution to yield a total volume of 200 μL.
All shRNA molecules used in this study were synthesized
by Santa Cruz Biotechnology. Three target-specific lenti-
viral vector plasmids, each encoding 19 nt–25 nt (plus a
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hairpin) shRNAs, were designed to knockdown the gene
expression. These plasmids are as follows: MLL3 shRNA
plasmid (m: sc-29436-SH), control plasmid (sc-108060),
and copGFP Control Plasmid (sc-108083). The copGFP
control plasmid is a lentiviral vector plasmid encoding
the copGFP fluorescent protein in mammalian cells.
The control plasmid encodes a nonfunctional protein.
Following the in vivo transfection, the efficacy of the
gene transfer was assessed by an immunohistochemi-
cal analysis of GFP and the podocyte markers nephrin
and NEPH-1.
Chromatin immunoprecipitation assay
Molecular events in the kidneys of LPS-treated mice
were monitored using a chromatin immunoprecipitation
(ChIP) assay to immunopurify soluble chromatinized
H3K4 me3 sequences using specific antibodies and the
EpiQuik ChIP kit (EPIGENTEK, Brooklyn, NY, USA).
The antibodies used included normal mouse IgG as the
negative control, anti-RNA polymerase II as the positive
control, and anti-H3K4 me3 (EPIGENTEK, Brooklyn,
NY, USA). The DNA concentration was quantified using
a NanoDrop UV spectrometer (NanoDrop Technologies,
Wilmington, DE, USA). A SYBR green assay (LightCy-
cler 480 SYBR Green I Master; Roche, Mannheim,
Germany) was performed using the 7300HT Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA,
USA) using primers for mouse cathepsin L (EpiTect
ChIP qPCR Assays, QIAGEN).
Podocyte culture
Conditionally immortalized mouse podocytes (podocyte
cell line E11) cloned from the outgrowth of glomeruli
isolated from H-2 kb-tsA58 transgenic mice were pur-
chased from Cell Lines Service (CLS cell line service,
Eppelheim, Germany). Podocytes were cultured accord-
ing to the method of Endlich et al. [9]. Undifferentiated
podocytes were cultured in RPMI1640 medium (GIBCO,
USA) with 10% fetal bovine serum (FBS) (GIBCO) in an
incubator at 33 °C in 5% CO2. Podocytes were cultured
at 38 °C in RPMI1640 medium for a minimum of 14 days
to allow for complete differentiation [10].
Lentiviral vector plasmids each encoding MLL3
shRNAs (sc-62624-SH; Santa Cruz Biotechnology) and
a transfection reagent (sc-108061) were used for the
inhibition of MLL3 expression in E11 cells. Lentiviral
vector plasmids each encoding GFP shRNA (sc-
45924-SH; Santa Cruz Biotechnology) were used to
confirm the efficiency of the transfection. After trans-
duction, the E11 line expressing the shRNA was used
for the Western blot analysis and acid extraction of
histones followed an ELISA assay for H3K4 trimethy-
lation and ChIP assay.
Isolation and co-culture of peritoneal macrophages with
podocytes
Peritoneal macrophages (pMACs) were isolated from
B57CL/6 mice. A volume of 2 mL of 3% thioglycollate
(Sigma-Aldrich, USA) was injected into the abdominal
cavity to activate pMACs and thus, enable the harvest of
an optimal yield. After 3 days, the mice were killed with
an overdose of sodium pentobarbital via a subcutaneous
injection. Then, 10 mL of cold sterile RPMI 1640 was
injected intraperitoneally, and peritoneal lavage fluids were
collected using sterile syringes. For juxtacrine co-cultures,
pMACs were seeded in a Falcon® cell culture insert for six-
well plates (0.4 μm, high density pore, 1 × 105 cells/well,
Corning, NY, USA). After incubation at 37 °C for 4 h to
allow the pMACs to adhere to the surface of the cell culture
insert, the non-adherent cells were removed. These cell cul-
ture inserts were placed into six-well plates seeded with
podocytes (1 × 106 cells/well) after the trans induction of
control shRNA or MLL3 shRNA. These juxtacrine co-
cultured cells were incubated with serum-free RPMI1640
(control), or serum-free RPMI1640 with 2 μg/mL lipopoly-
saccharide (LPS). At 24 h, podocytes from control or LPS
groups transfected with each control or MLL3 shRNA were
subjected to an H3K4 me3 assay, Western blot, and ChIP
assay.
Statistical analysis
Statistical comparisons of data were made using a one-
way repeated-measurements ANOVA followed by a
Dunnett’s test for multiple comparisons. The Mann-
Whitney U test was used to compare variables between
the two groups. The results are expressed as the mean ±
standard error (SE). Analyses were performed using add-
in statistical software from Excel (Ekuseru Toukei 2010,
Social Survey Research Information Co., Ltd., Tokyo
Japan). A two-tailed probability value < 0.05 was consid-
ered to be statistically significant.
Results
Distribution of histone H3K4 me3 in human primary
acquired glomerular diseases
H3K4 me3 exhibited a pattern of nuclear expression in
the podocytes of kidneys from patients with membranous
nephropathy (MN; Fig. 1). The co-localization of H3K4
me3 (Fig. 1c) and Wilm’s tumor-1 (WT-1) (Fig. 1a), a
podocyte marker, was demonstrated by double immuno-
fluorescence (Fig. 1d) in the glomeruli of patients with
MN. H3K4 me3 may also be localized in mesangial cells
and endothelial cell nuclei in the glomeruli.
Pathophysiological role of histone H3K4 me3 in patients
with MN
The expression of H3K4 me3 was evaluated immunohis-
tochemically in patients with nephrotic syndrome who
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were diagnosed with primary MN (Table 1). None of the pa-
tients had received immunosuppressive therapy before the
renal biopsy. Primary MN was diagnosed by immunostain-
ing of the phospholipase-A2-receptor (PLA2R1) (Fig. 2c,
Case 1 in Table 1) and sub-epithelial deposits as determined
by electron microscopy (Fig. 2d, Case 1 in Table 1). All biop-
sies exhibiting membranous histology were graded by dis-
ease stage as estimated by the electron microscopy findings.
Staining for H3K4 me3 was observed in the podocytes from
the biopsies of all six patients with MN, with the intensity of
staining varying between specimens.
The expression of H3K4 me3 and cathepsin L in pa-
tients with control (ConA, N = 3) and MN (N = 6) in a
series of consecutive patients were examined (Table 1).
Staining for H3K4 me3 (left side in Fig. 2a) was observed
in the podocytes from the biopsies of the controls, in
which H3K4 me3 was found to be co-localized with ca-
thepsin L in the glomeruli (center and right side in
Fig. 2a). The overlapping expression of H3K4 me3 and
cathepsin L in patients with MN (Fig. 2b and e) was signifi-
cantly higher than that of the controls (ConA, Fig. 2a and e).
The expression of H3K4 me3 and cathepsin L in patients of
other age-matched controls, which were not a series of con-
secutive patients (ConB, N= 3, Table 2) and MN (N= 6,
Table 1) were examined. The overlapping expression of
H3K4 me3 and cathepsin L in patients with MN was signifi-
cantly higher than that of the ConB (Fig. 2e).
The overlapping expression of H3K4 me3 and cathepsin
L in patients with nephrotic syndrome diagnosed as
minimal change (N = 2) and FSGS (N = 2) and amyloidosis
(N = 3) were examined (Table 2). The overlapping expres-
sion of H3K4 me3 and cathepsin L in patients with MN
was significantly higher than in those with MC, FSGS, and
alyloidosis (Fig. 2f).
The expression of H3K4 me3 and synaptopodin were
examined in the controls and patients with MN (Fig. 3a).
As shown in Fig. 3b, a positive correlation was observed
between the intensity of H3K4 me3 staining and the
(A) (B)
(C) (D)
Fig. 1 Localization of trimethylated histone H3K4 in human kidney glomeruli. Immunohistochemical staining indicates the co-localization of
trimethyl-histone H3K4 (H3K4 me3) with the podocyte marker WT-1. The overlapping staining for WT-1 (green, a) and H3K4 me3 (red, c) results in
a merged image (yellowish, d); nuclei are stained blue using Hoechst 33342 (b)
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extent of proteinuria in patients with primary MN.
The expression levels of synaptopodin in the podo-
cytes were inversely correlated with the H3K4 me3
expression (Fig. 3c) as well as proteinuria, consistent
with previous reports [11] (Fig. 3d). Thus, the overex-
pression of H3K4 me3 in podocytes was associated
with the downregulation of synaptopodin, an actin-
associated protein, and with increased proteinuria in
patients with MN. The enhanced expression of
PLA2R1 showed no significant correlation with the
degree of proteinuria or H3K4 me3 expression (data
not shown). The intensity of H3K4 me3 staining did
not directly correlate with the stage of disease accord-
ing to the Ehrenreich-Churg classification (data not
shown).
Elevated histone H3K4 me3 levels in the podocytes of
kidneys from LPS-treated mice
LPS-treated mice exhibited progressive proteinuria (ve-
hicle, 0.50 AU/creatinine ± 0.69 AU/creatinine; LPS,
1.59 AU/creatinine ± 1.38 AU/creatinine). The immuno-
histochemical analysis revealed that H3K4 me3 was lo-
cated primarily in the podocytes of LPS-treated mice
(Fig. 4). LPS-treated mice exhibited podocyte swelling
(Fig. 5a and d) similar to those observed with nephrotic
syndrome. Immunohistochemical results confirmed that
H3K4 me3 was upregulated in kidney podocytes 2 days
following LPS administration (Fig. 5b and e). H3K4 me3
levels increased significantly over that of controls
(vehicle alone) 2 days following LPS administration
according to the Western blot analysis (Fig. 6a).
Synaptopodin and cathepsin L levels in the kidneys of
LPS-treated mice
Synaptopodin expression was analyzed immunohisto-
chemically 2 days after LPS administration (Fig. 5c
and f ). Synaptopodin expression was significantly lower
in LPS-treated mice than in the untreated controls
(vehicle alone) (Fig. 5c and f). Cathepsin L expression was
detected in podocytes using immunocytochemistry (data
not shown). We next examined whether a similar upregu-
lation of cathepsin L occurs in the LPS-treated murine
model. As demonstrated by a Western blot analysis, ca-
thepsin L levels were significantly higher in LPS-treated
mice 2 days after administration than in the untreated
controls (vehicle alone) (Fig. 6b).
H3K4 me3 levels at the cathepsin L promoter in the
kidneys of LPS-treated mice
To directly link H3K4 me3 to the cathepsin L locus, we
conducted chromatin immunoprecipitation experiments
to examine the changes in histone H3K4 me3 methyla-
tion patterns at the transcription initiation site of ca-
thepsin L. The levels of H3K4 me3 at the cathepsin L
promoter were significantly higher 2 days after LPS ad-
ministration than in the untreated controls (vehicle
alone) (Fig. 6c). These results suggest that the LPS-
induced increase in cathepsin L expression is caused, at
Table 1 Characteristics of patients with primary membranous nephropathy
Case Age Sex sCre M-alb/cre (mg/g cre) Stage HT Duration of disease prior
to biopsy (months)
Hematuria Previous Treatment
MN1 65 M 0.65 2931 II + 24 +/− ARB
CCB
Statin
MN2 78 M 0.95 1120 III + 12 2+ ARB
CCB
MN3 72 M 0.86 8188 I - 8 3+ -
MN4 65 M 1.25 4306 II - 4 2+ -
MN5 46 M 0.93 4136 I + 2 3+ ARB
MN6 79 M 0.90 3168 I + 6 2+ ARB
CCB
Statin
ConA1 33 M 0.60 12 - - - 2+ -
ConA2 27 F 0.60 7.6 - - - 1+ -
ConA3 46 M 0.98 6.2 - - - 2+ -
sCre serum creatinine (mg/dL), stage the stage of disease according to the Ehrenreich–Churg classification, ARB angiotensin II type 1 receptor blocker, CCB calcium
channel blocker, ConA1-3 three controls in a series of consecutive patients, which were subjected to a renal biopsy with finding of microhematuria without
proteinuria and no pathological findings of glomerulonephropathy
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least in part, by epigenetic histone H3K4 me3 modifica-
tions at the promoter.
Administration of MLL3 shRNA restored the LPS-induced
upregulation of H3K4 me3 and cathepsin L and restored the
downregulation of synaptopodin and podocyte swelling
To determine whether H3K4 me3 was necessary for the
altered protein expression observed in podocytes, we
conditionally downregulated MLL3, an integral compo-
nent of H3K4 methyltransferase, in the glomerular
podocytes of mice. LPS-treated mice were transfected
with 20 μg of shRNA targeting MLL3, a control, and
GFP-containing plasmid. The efficacy of the shRNA
transfection was determined on the basis of the transfec-
tion of GFP (Fig. 7f ). GFP was detected by
immunohistochemistry using an anti-GFP antibody that
was expressed in the kidney podocytes from mice trans-
fected with GFP shRNA (Fig. 7f ), with an expression
pattern similar to that of nephrin and NEPH-1 (data not
shown) in the kidneys of LPS-treated mice.
The upregulation of H3K4 me3 was significantly inhib-
ited by MLL3 shRNA compared with control shRNA as
determined by Western blotting (Fig. 7a and b) and an
ELISA using samples derived by acid extraction (Fig. 7c).
The upregulation of cathepsin L was significantly inhib-
ited by MLL3 shRNA compared with control shRNA de-
termined by a Western blot (Fig. 7d and e).
The LPS-induced attenuation of synaptopodin levels
was significantly restored by MLL3 shRNA compared with
the control shRNA as detected by immunohistochemistry
(A)
(B)
(C) (D) (E) (F)
Fig. 2 Expression of trimethylated histone H3K4 and cathepsin L in a patient with membranous nephropathy. Immunohistochemical staining
indicates the overlapping staining for H3K4 me3 (green, left side) and cathepsin L (red, center) resulting in the merged image (yellowish, right side)
in the control (a) and MN patient (b). Biopsies showing primary MN were diagnosed by positivity for PLA2R1 staining (c, Case 1 in Table 1) and
subepithelial deposits according to electron microscopy findings (d, Case 1 in Table 1). The overlapping expression of H3K4 me3 and cathepsin L
in patients with MN (N = 6) was significantly higher than in those of the ConA or ConB (e). ConA, control obtained in a series of consecutive
patients (N = 3); ConB, age-matched healthy control, which were not in a series of consecutive patients (N = 3) (e). The overlapping expression of H3K4
me3 and cathepsin L in patients with MN was significantly higher than that of minimal change or FSGS or amyloidosis (f). H3K4 me3, histone H3K4
trimethylation; MN, membranous nephropathy; MC, minimal change; FSGS, focal segmental glomerular sclerosis; Amyl, AL amyloidosis. *P < 0.05 vs.
ConA; #P < 0.05 vs. MN. Data are expressed as the mean ± SE
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Table 2 Characteristics of patients with nephrotic syndrome and healthy controls
Case Age Sex sCre M-Alb/cre (mg/g cre) HT Duration of disease prior
to biopsy (months)
Hematuria Previous Treatment
FGS 1 45 M 0.61 6087 + 1 2+ ARB
Statin
FGS 2 47 M 3.50 4338 + 12 1+ ARB
CCB
statin
MC 1 24 M 0.71 3376 - 1 2+ -
MC 2 27 M 0.65 2868 - 1 1+ -
Amy1 73 M 0.83 4680 - 4 1+ -
Amy 2 82 F 0.65 5381 + 1 2+ ARB
Statin
Amy 3 72 F 0.9 3600 - 48 2+ ARB
ConB1 44 M - - - - - -
ConB2 66 M - - - - - -
ConB3 78 M - - - - - -
sCre serum creatinine (mg/dL), ARB angiotensin II type 1 receptor blocker, CCB calcium channel blocker, MC minimal change, FGS focal segmental glomerular
sclerosis, Amy AL amyloidosis, ConB1-3 three age-matched control, which were not obtained in a series of consecutive patients
(A)
(B) (C) (D)
Fig. 3 Association between histone H3K4 me3 and the expression of synaptopodin and proteinuria in patients with MN. Expression of H3K4 me3
(left side in a), synaptopodin (center in a), and the merged image (right side in a) are shown. The level of H3K4 me3 expression was positively
correlated with albuminuria (b), and the level of H3K4 me3 expression was inversely correlated with the level of synaptopodin expression in the
podocytes of patients with MN (c). The level of synaptopodin expression was inversely correlated with the level of albuminuria (d). MN,
membranous nephropathy; H3K4 me3, histone H3K4 trimethylation
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(Fig. 8a and b). Electron microscopy also showed this
suppressive effect of MLL3 shRNA with respect to the
podocyte swelling induced by LPS (Fig. 8c and d).
These results further support a key role of MLL3 in
modulating H3K4 me3 to increase cathepsin L expres-
sion, decrease synaptopodin expression, increase podo-
cyte swelling, and suggests a role of MLL3 shRNA in
reversing the effects of LPS administration.
Administration of MLL3 shRNA restored renal function
and attenuated proteinuria
The urine albumin level, a marker of glomerular dam-
age, was significantly lower in mice administered MLL3
shRNA than in those given the control shRNA (control
shRNA, 2.05 AU/creatinine ± 0.60 AU/creatinine; MLL3
shRNA, 1.04 AU/creatinine ± 0.58 AU/creatinine). The
serum creatinine level, a marker of glomerulofiltration,
was significantly lower in mice administered MLL3
shRNA than in those given control shRNA in the LPS
model (control shRNA, 2.06 mg/dL ± 0.50 mg/dL; MLL3
shRNA, 1.40 mg/dL ± 0.40 mg/dL). Thus, MLL3 shRNA
not only decreased LPS-induced increases in H3K4 me3 but
also ameliorated the renal dysfunction and albuminuria.
Examination using cultured podocytes
The effects of MLL3 shRNA were examined using cul-
tured mouse podocytes. Mouse podocyte cells (E11 cell)
cultured in a basal medium with 10% FCS were treated
with MLL3 shRNA or control shRNA. The expression
levels of H3K4 me3 were determined by a sandwich
ELISA, and the expression levels of cathepsin L and
synaptopodin were analyzed by Western blot.
The effects of LPS were examined to cause increased
H3K4 methylation in podocytes. LPS did not directly
cause increased H3K4 methylation in the cultured
podocytes. In the co-cultured podocytes with peritoneal
macrophages stimulated with LPS, increased H3K4 me3
was shown in podocytes compared with the unstimu-
lated cells (Fig. 9a). These data suggest that cytokines
derived from macrophages stimulated with LPS cause
increased H3K4 me3 in podocytes. We treated MLL3
shRNA-transduced cultured podocytes and compared
them to the control shRNA transduced podocytes
followed by analysis of H3K4 methylation under these
conditions. In the samples extracted from E11 cells stim-
ulated with cytokines derived from macrophages using a
co-cultured system that followed the acid extraction
method and sandwich ELISA, MLL3 shRNA administra-
tion decreased H3K4 me3 compared to that of cells ad-
ministered the control shRNA (Fig. 9a). MLL3 shRNA
administration decreased the cathepsin L protein expres-
sion compared to that of cells administered with control
shRNA (Fig. 9b). In addition, in the cultures stimulated
with cytokines derived from co-cultured macrophages,
MLL3 shRNA increased the expression of synaptopodin




Fig. 4 Localization of histone H3K4 me3 in mouse kidney glomeruli. Immunohistochemical staining indicates the co-localization of trimethyl-histone
H3K4 (H3K4 me3) with the podocyte marker WT-1. The overlapping staining for WT-1 (red, a) and H3K4 me3 (green, b) results in the merged image
(yellowish, c) as indicated by the arrow
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(A) (B) (C)
Fig. 6 Expression of H3K4 me3 and cathepsin L and the determination of H3K4 me3 level on the promoter region of cathepsin L in the LPS
model. Histone H3K4 me3 levels (a) and cathepsin L (b) levels were significantly higher in LPS-treated mice than in the controls (vehicle alone) as
determined by a Western blot analysis. A chromatin-immunoprecipitation assay demonstrated that the amount of H3K4 me3 at the cathepsin L
promoter was significantly higher in the LPS-treated mice than in the controls (vehicle alone) (c). *P < 0.05 vs. Veh. LPS, lipopolysaccharide treated




Fig. 5 Podocyte swelling and the expression of H3K4 me3 and synaptopodin in the LPS model. Electron microscopy reveals podocyte swelling
induced by LPS administration (right side in a and d) compared with the controls (vehicle alone, left side in a and d). The expression of histone
H3K4 me3 was significantly higher following LPS administration (right side in b and e) than in the controls (vehicle alone, left side in b and e).
Synaptopodin expression was significantly lower following LPS administration (right side in c and f) compared to that of the controls (vehicle
alone, left side in c and f). *P < 0.05 vs. Veh. LPS, lipopolysaccharide treated mice; Veh, vehicle treated mice; H3K4 me3, histone H3K4
trimethylation; N = 10. Data are expressed as the mean ± SE
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shRNA (Fig. 9c). In chromatin immunoprecipitation
(ChIP) assays in E11 cells stimulated with cytokines de-
rived from co-cultured macrophages, levels of H3K4
me3 at the cathepsin L promoters were significantly
lower in E11 cells treated with MLL3 shRNA after 72 h
administration compared with the control shRNA
(Fig. 9d).
Discussion
Nephrotic proteinuria associated with MN reflects a
profound podocyte dysfunction; however, the pathogenic
mechanism underlying this disorder remains unclear.
We used immunohistochemical staining and electron
microscopy to investigate the renal biopsies from six pa-
tients with nephrotic syndrome and PLA2R1-positive
primary MN. We observed the co-localization of H3K4
me3 and the podocyte marker WT-1. The overlapping
expression of H3K4 me3 and cathepsin L in patients
with MN was significantly elevated compared with the
controls. Elevated H3K4 me3 in patients with MN was
associated with the downregulation of synaptopodin and
positively associated with proteinuria. However, patient
characteristics, including the mean age, differed signifi-
cantly between the groups. The similarity in sex and age
of patients with MN in this study may contribute to the
observed relationship between histone H3K4 me3 and
proteinuria or the expression of synaptopodin.
We also observed that proteinuria and renal dysfunc-
tion in an LPS-induced murine model of the disease was
accompanied by an increase in histone H3K4 me3 and
cathepsin L protein, decreased levels of synaptopodin
protein, and an increase in podocyte swelling. These fea-
tures were restored by MLL3 shRNA administration.
The high efficacy of an in vivo transfection may result
from the increased filtration in the basement membrane
of the LPS model, in addition to the use of a conjugate-
containing anti-nephrin antibody that recognizes the
extracellular domain of nephrin in podocytes. Moreover,
it may allow nephrin internalization to an intracellular
site following its dislocation from the plasma membrane.
The effects of MLL3 shRNA were examined using the
mouse podocytes under the condition stimulated with
cytokines derived from co-cultured macrophages. MLL3
shRNA administration decreased H3K4 me3 compared
to that of E11 cells administered with the control shRNA
as determined by acid extraction followed by a sandwich
ELISA. MLL3 shRNA administration increased the ex-
pression of synaptopodin compared to that administered
with the control shRNA. MLL3 shRNA administration
decreased cathepsin L protein expression compared to
(A) (B) (C)
(D) (E) (F)
Fig. 7 Effect of MLL3 shRNA on the expression of histone H3K4 me3 and cathepsin L in the LPS model. Expression of H3K4 me3 was determined by
Western blot (a and b) and an ELISA using material isolated by acid extraction (c). The upregulated expression of H3K4 me3 (a–c) and cathepsin L (d and e)
was significantly lower in MLL3 shRNA compared with control shRNA in the LPS-treated mice. GFP protein detected by immunohistochemistry using an
anti-GFP antibody was clearly detected on the podocytes of kidneys transfected with GFP shRNA (f). *P< 0.05 vs. Veh. LPS, lipopolysaccharide treated mice;
Veh, vehicle treated mice; H3K4 me3, histone H3K4 trimethylation; total H3, total histone H3; N= 10. Data are expressed as the mean± SE
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that of cells administered with the control shRNA.
Levels of H3K4 me3 at the cathepsin L promoters were
significantly lower in E11 cells treated with MLL3
shRNA than in those treated with the control shRNA.
Although these data do not exclude the possibility that
H3K4 methylation may occur in mesangial cells and
endothelial cell nuclei, these data support an important
role for epigenetic H3K4 me3 modification in the podo-
cytes of kidney glomeruli.
Our results indicate a relationship between H3K4
me3, proteinuria, and synaptopodin with respect to MN
pathophysiology. We observed increased H3K4 me3, en-
hanced cathepsin L, and decreased synaptopodin expres-
sion in the kidney podocytes of mice treated with LPS
compared to that of the controls. The significance of the
induction of H3K4 me3 in the upregulation of cathepsin
L is further underscored by the finding that H3K4 me3
induces cathepsin L transcription as measured by a ChIP
assay and real-time RT-PCR in both the LPS model and
cultured podocytes. Cathepsin L is a potent endopro-
tease primarily responsible for the final breakdown of
proteins within lysosomal compartments [12]. The im-
portance of podocyte cathepsin L is highlighted by both in
vitro data and animal models of glomerular diseases, as
well as expression studies of human biopsies [8, 13, 14].
Two substrates of cytosolic cathepsin L have been
described in podocytes: 1) dynamin [14] and 2) synapto-
podin [11, 15]. Both of these proteins contribute to the F-
actin structure in normal podocyte foot processes by pro-
moting foot process effacement following the enzymatic
processing by cathepsin L. Synaptopodin-deficient mice
display impaired recovery from protamine-sulfate-induced
foot process effacement and LPS-induced nephrotic
syndrome [16]. A recent study reported that the beneficial
effect of cyclosporine A (CsA) on proteinuria results from
the stabilization of the actin cytoskeleton in kidney
podocytes [11]. CsA blocks the calcineurin-mediated de-
phosphorylation of synaptopodin, thereby preserving the
phosphorylation-dependent synaptopodin/14-3-3b inter-
action [17]. Preservation of this interaction protects
synaptopodin from cathepsin-L-mediated degradation. A
recent study investigated the effects of targeting dynamin’s
oligomerization cycle with Bis-T-23, which promotes
actin-dependent dynamin oligomerization in whole ani-
mals [18]. Bis-T-23 ameliorated or prevented proteinuria
and diminished the mesangial matrix expansion in genetic
and chronic models of glomerular disease in rodents. This
study suggests the feasibility of treating a diverse range of
glomerular kidney diseases by modulating actin dynamics.
In light of these findings, our observation that H3K4 me3
is associated with the downregulation of synaptopodin in





Fig. 8 Effect of MLL3 shRNA on synaptopodin expression and podocyte swelling in the LPS model. LPS-induced decreased synaptopodin expression
was significantly restored by MLL3 shRNA compared with control shRNA as detected by immunohistochemistry (a and b). Electron microscopy
showed the suppressive effect of MLL3 shRNA on LPS-induced podocyte swelling (c and d). *P < 0.05 vs. control shRNA. LPS, lipopolysaccharide treated
mice; Cont, control; N = 10. Data are expressed as the mean ± SE
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can be explained by the increased degradation of synapto-
podin due to the upregulation of cathepsin L. Proteinuria
in an LPS-induced murine model and patients with MN
may result from changes in podocyte morphology and
motility following alterations in the foot-process architec-
ture. Strategies to protect synaptopodin from degradation
may provide a promising starting point for the develop-
ment of antiproteinuric drugs.
We observed that the LPS-induced proteinuria, im-
paired renal function, and altered expression of H3K4
me3, cathepsin L, and synaptopodin were restored by
the administration of shRNA against MLL3, a compo-
nent of the histone H3K4 methyltransferase complex.
This result confirms the involvement of H3K4 methyla-
tion in the mechanism of LPS-induced proteinuria, as
the recruitment of MLL3 to the chromatinized cathepsin
L gene is known to mediate histone methylation and its
subsequent gene expression. This result was confirmed
in cultured podocytes. Dysregulation of MLL3 activity is
associated with multiple cancers [19–21], and the tar-
geted inactivation of MLL3 H3K4 methylation in mice
results in ureter epithelial tumors [22]. These findings
suggest that specific agonists/antagonists of MLL3/4
H3K4MT activity could be useful for treating a variety of
disorders. Similar to MLL3, PTIP is a component of the
histone H3K4 methyltransferase complex. This protein
is required for the enzymatic activity of the complex.
PTIP knockout mice demonstrate podocyte dysfunction
[23], suggesting a maintenance function for PTIP-
mediated H3K4 me3 in podocytes. Urine albumin levels
of PTIP knockout mice were 10- to 30-fold higher than
those of WT mice. Moreover, the podocyte foot pro-
cesses of the knockout mice appeared much more ir-
regular and flattened under electron microscopy. This
observation is in contrast to our finding that an MLL3
knockdown ameliorated the effects of LPS by suppress-
ing H3K4 methylation. We speculate that these contrast-
ing results stem from differences in the intensity of
H3K4 me3 inhibition. A previous report showed that
MLL3 interacts with transcription factors and facilitates
the recruitment of the PTIP complex to target gene pro-
moters [24]. We further observed that the
(A) (B)
(C) D)
Fig. 9 Effect of MLL3 shRNA on synaptopodin and cathepsin L expression and histone H3K4 me3 levels and the determination of H3K4 me3 level on the
promoter region of cathepsin L in cultured mouse podocytes co-cultured with LPS-stimulated peritoneal macrophages. In podocytes co-cultured with
peritoneal macrophages stimulated with LPS, increased H3K4 me3 was found compared to untreated podocytes (Veh) (a). MLL3 shRNA administration
decreased H3K4 me3 compared to that of cells administered with control shRNA (a). MLL3 shRNA administration also decreased the level of cathepsin L
protein expression compared to that of cells administered the control shRNA (b). MLL3 shRNA increased the expression of synaptopodin compared to that of
the cells administered control shRNA in cultures stimulated with cytokines derived from co-cultured macrophages (c). In chromatin immunoprecipitation
(ChIP) assays with E11 cells stimulated with cytokines derived from co-cultured macrophages, the stimulated levels of H3K4 me3 at the cathepsin L promoters
were significantly lower in E11 cells treated with MLL3 shRNA 72 h post-administration compared with the control shRNA (d). *P< 0.05 vs. Veh. Veh, untreated
podocytes; Cont, control shRNA; H3K4 me3, histone H3K4 trimethylation; total H3, total histone H3; N=4. Data are expressed as the mean± SE
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downregulation of MLL3 results in changes in the tran-
scriptional profile of terminally differentiated podocyte
cells, which ultimately protects against the glomerular
disease phenotype induced by LPS. Our results demon-
strate a function for MLL3-mediated H3K4 methylation,
and indicate a novel role for H3K4 me3 in podocyte
motility.
The median age of onset of MN is in the early 50s, an
MN has been established as the most important cause of
the nephrotic syndrome in elderly patients (aged > 65 years).
Accumulating evidence also suggests that aging is associated
with systemic and vascular inflammation [25]. Circulating
inflammatory cytokines are elevated in some older adults
[26, 27], and chronic exposure to inflammation is thought
to be closely related to the development and progression of
renal injury [28–30]. Previous studies have shown that
the LPS-mediated NF-kB signaling pathway, which
plays a critical role in the inflammatory response, is in-
volved in H3K4 me3 redistribution in monocyte-derived
dendritic cells [31, 32]. Silencing of MLL inhibits both
H3K4 me3 enrichment and miRNA expression, and
affects TNF-α production [31, 32]. Our data using a co-
cultured system with podocytes and peritoneal macro-
phages suggests that cytokines derived from macrophages
stimulated with LPS cause increased H3K4 me3 in podo-
cytes. Thus, MN pathogenesis may involve the induction
of H3K4 me3 by inflammatory cytokines, leading to an in-
creased expression of cathepsin L and a decreased expres-
sion of synaptopodin. These changes were observed to
induce the deterioration of renal function and proteinuria
in LPS-treated mice, and were consistent with the findings
in patients with MN.
Study limitations
There were several limitations in the current study.
Firstly, age-matched control samples from healthy do-
nors were not obtained in a series of consecutive pa-
tients and there is difference in the methods for
preparation of fixation and embedding. Moreover, there
was a difference in the serum creatinine levels and mean
age between MN and minimal change, FSGS, or amyl-
oidosis. Finally, the LPS-induced murine model is not a
suitable model for MN. Other models, including the cat-
ionic BSA injection or heymann nephritis model will
also need to be examined in the future.
Conclusions
Epigenetic H3K4 me3 modification at the cathepsin L pro-
moter increases cathepsin L expression and is associated
with podocyte dysfunction and MN pathophysiology.
Therefore, targeting this epigenetic signature of histone
H3K4 me3 may be an effective strategy to ameliorate the
consequences of MN.
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